P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 198 400 KRW -0.8% Market Closed
Market Cap: 2.1T KRW
Have any thoughts about
PharmaResearch Co Ltd?
Write Note

PharmaResearch Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaResearch Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Income from Continuing Operations
â‚©90.8B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Income from Continuing Operations
â‚©320.9B
CAGR 3-Years
-19%
CAGR 5-Years
7%
CAGR 10-Years
10%
SK Bioscience Co Ltd
KRX:302440
Income from Continuing Operations
â‚©22.3B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Income from Continuing Operations
-â‚©22.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Income from Continuing Operations
â‚©119.4B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Income from Continuing Operations
-â‚©3.6B
CAGR 3-Years
34%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
2T KRW
Industry
Biotechnology

PharmaResearch Co., Ltd. engages in the research and development of refined raw materials for cell and tissue regeneration through marine bio technology. The company is headquartered in Gangneung, Gangwon-Do. The company went IPO on 2015-07-24. The firm produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The firm mainly provides its products in domestic market.

Intrinsic Value
248 805.39 KRW
Undervaluation 20%
Intrinsic Value
Price
P

See Also

What is PharmaResearch Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
90.8B KRW

Based on the financial report for Jun 30, 2024, PharmaResearch Co Ltd's Income from Continuing Operations amounts to 90.8B KRW.

What is PharmaResearch Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
47%

Over the last year, the Income from Continuing Operations growth was 58%. The average annual Income from Continuing Operations growth rates for PharmaResearch Co Ltd have been 28% over the past three years , 47% over the past five years .

Back to Top